MRNA

#561
Moderna, Inc. - Common Stock
47.1 9 USD
-0.80%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
47.19
47.19
年范围
22.29
59.55
日变化
-0.80%
每月变动
+2.12%
6个月变化
+88.38%
年变化
+78.75%
前一天收盘价
47.5 7
Open
47.1 9
最低价
47.1 9
High
47.1 9
交易量
365
展开完整图表 完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 18.72 B
  • Employee 4 700
  • Founded N/A
  • CEO Stéphane Bancel
  • Website www.modernatx.com
  • Headquarter Delaware, United States
  • FIGI BBG003PHHZT1
  • Industry 生物技术
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-6.24
市销率
8.91

Moderna, Inc. - Common Stock

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.

新闻